26A simple aspirin-inducible system has been developed by employing the P sal promoter and SalR 27 regulation system originally from Acinetobacter baylyi ADP1, which has been cloned into E. coli 28 for characterisation of gene circuits and induction of novel SimCells (simple cells). Mutagenesis 29 at the DNA binding domain (DBD) and chemical recognition domain (CRD) of the SalR protein 30 in A. baylyi ADP1 suggests that inactive SalR i can compete with activated SalR a , occupying the 31 binding position of P sal promoter. The induction of the P sal promoter was compared in two 32 different designs in E. coli: simple regulation (SRS) and positive autoregulated system (PAR).
33Both regulatory systems were induced in a dose-dependent manner in the presence of aspirin in 34 the range of 0.05-10 µM. Over-expression of SalR in the SRS system reduces both baseline 35 leakiness and inducible strength of P sal promoter. A weak SalR expression significantly improve 36 the inducible strength, which is in a good agreement of the proposed hypothesis of SalR i /SalR a 37 competitive binding. The PAR system provides a feedback loop that fine-tunes the level of 38 SalR, displaying inducible strength. A mathematical model based on SalR i /SalR a competitive 39 binding hypothesis was developed, which not only reproduces the observed experimental 40 results but also predict the performance of a new gene circuit design. The aspirin-inducible 41 systems were also functional in probiotic strain E.coli Nissle 1917 (EcN) and SimCells produced 42 from E. coli MC1000 ΔminD. The well-characterised and modularised aspirin-inducible gene 43 circuits would be useful biobricks for bacterial therapy in environment and medical applications.44 45 46 47 48 49 50 51 52 , -3 -Introduction 53Synthetic biology has the potential to engineer bacteria for disease diagnosis (1) and cancer 54 therapy (2). Since bacteria colonise human skin, gastrointestinal tracts, the respiratory and 55 reproductive systems (3), and many bacteria preferentially associate with tumours (2), they are 56 ideal agents for diagnosis and therapy. Bacterial therapy has shown great potential in 57 biomedicine, with applications including the regulation of a host organism's energy metabolism
58(4), the delivery of drugs (5), as well as modulating chemotherapy, radiotherapy, and 59 immunotherapy treatments for cancer (6).
60Advances in the utilisation of feedback-based synthetic circuits for biomass yield optimization 61 (7), spatial control of tissue regeneration (8), and bacterial diagnosis therapy (9-12) have been 62 characterised and implemented in in vivo studies. An ideal bacterial design for environment and 63 medicine should have the following traits. The specific bacterial chassis should be safe for 64 human applications. The inducer should have no side effects on human health, and should be 65 able to trigger different levels of gene expressions in response to different inducer 66 concentrations. Gene circuits should have minimal cross-talk and only be triggered by a spec...